婦人科用医薬品の世界市場レポート 2024

婦人科用医薬品の市場規模は、今後数年間で大幅な成長が見込まれています。 2028年には5.4%の年間複合成長率（CAGR）で541億米ドルに成長すると予想されます。予測される成長は、避妊薬やホルモン補充療法（HRT）の意識と使用の増加、加齢に伴う婦人科がんの増加、卵巣がん症例の増加、婦人科疾患の有病率、ヘルスケア費の増加、子宮内膜症のメカニズムの理解への投資によって促進されます。主な動向としては、がんや子宮内膜症に対する新治療薬の発売、更年期ホルモン療法の開発、婦人科治療薬への研究投資、避妊効果に関する啓蒙活動、アンメットニーズに対する製品の発売、卵巣がんに対する抗体薬物複合体、ポートフォリオ拡大のための戦略的提携、がん治療における薬剤耐性に対処するための併用療法への注力などが挙げられます。

卵巣がんに罹患する女性の数の予想される増加により、世界の婦人科用医薬品市場の成長が促進されると予想されます。女性の生殖器系の一部として卵巣に発生する卵巣がんは、対象を絞った治療選択肢を提供し、生存率を高め、患者の生活の質を向上させる婦人科用医薬品によって効果的に管理されています。グロボカンの推計によると、卵巣がんの世界罹患数は2040年までに43万4,184人に達すると予測されており、それにより近い将来、婦人科用薬の需要が高まると予想されています。

年齢は、糖尿病、肥満、神経変性疾患、がんなどのさまざまな病気の重大な危険因子として機能します。特に、初経の早期や閉経の遅れなど、女性の生殖周期の乱れはホルモンの不均衡を引き起こし、人生の後期におけるがんのリスクを高めます。子宮内膜がんと卵巣がんは高齢の女性の間で蔓延しており、かなりの死亡率の原因となっています。これらのがんの発生率は年齢とともに増加し、通常は約60～70歳でピークに達します。さらに、子宮頸がんは一般に50歳前後で診断されますが、膣がんや外陰がんは通常、それより遅く、67歳ごろに診断されます。たとえば、米国がん協会は、2022年に米国で子宮頸がんが新たに14,000人発生すると推定しています。加齢に伴う婦人科がんの増加により、今後数年間で市場が拡大すると予想されます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の婦人科用医薬品市場、治療別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• ホルモン療法
• 非ホルモン療法
• 世界の婦人科用医薬品市場、適応症別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 婦人科のがん
• 更年期障害
• 多嚢胞性卵巣症候群
• 避妊
• その他の適応症
• 世界の婦人科用医薬品市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 地域および国の分析

• 世界の婦人科用医薬品市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界の婦人科用医薬品市場、国別、実績および予測、2018-2023、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 婦人科用医薬品市場の競合情勢
• 婦人科用医薬品市場の企業プロファイル
  • Merck &Co. Inc.
  • AbbVie
  • Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Pfizer Inc.

第31章 その他の大手および革新的な企業

• Furukawa Electric
• Motherson Sumi
• LS Cables &Systems
• HUBER+SUHNER.
• Acome
• Yazaki Corporation
• Fujikura Ltd.
• Robert Bosch
• HELLA GmbH &Co. KGaA
• Coroplast Harness Technology Sp. z oo sp. k
• EK Elektrokabel FABRYKA KABLI Karolak i synowie sp. z oo
• Coroflex Poland Sp. z oo Sp. k.
• Eltrim Kable Sp. z o. o
• Anixter
• Allied Wire &Cable Inc

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Gynecology drugs pertain to the medical field specializing in the treatment of illnesses affecting the female reproductive system, encompassing care for women during pregnancy and childbirth. These drugs serve the purpose of treating various gynecological diseases that may impact the uterus, ovaries, and appendages.

The primary therapeutic categories within gynecology drugs include hormonal therapy and non-hormonal therapy. Hormonal therapy involves treatments that either add, block, or remove hormones to impede the growth of cancer cells reliant on hormones for their development. Non-hormonal therapy includes the use of anti-infective and anti-inflammatory agents, lubricants, moisturizers, as well as medications such as antidepressants, gabapentin, clonidine, among others. Gynecology drugs find application in treating conditions such as gynecological cancers, menopausal disorders, polycystic ovary syndrome, contraception, and more. These drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The gynecology drugs market research report is one of a series of new reports from The Business Research Company that provides gynecology drugs market statistics, including gynecology drugs industry global market size, regional shares, competitors with a gynecology drugs market share, detailed gynecology drugs market segments, market trends and opportunities, and any further data you may need to thrive in the gynecology drugs industry. This gynecology drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The gynecology drugs market size has grown strongly in recent years. It will grow from $41.56 billion in 2023 to $43.78 billion in 2024 at a compound annual growth rate (CAGR) of 5.4%. The expansion observed in the historical period can be attributed to several factors, including the introduction of drugs with novel mechanisms, increased availability of educational tools and awareness regarding menopause, a rise in the use of long-acting reversible contraceptives, shifts in lifestyles, heightened healthcare awareness and expenditure, government initiatives, and an increase in pharmaceutical research and development (R&D) expenditure.

The gynecology drugs market size is expected to see strong growth in the next few years. It will grow to $54.1 billion in 2028 at a compound annual growth rate (CAGR) of 5.4%. The forecasted growth is driven by increased awareness and use of contraceptives and hormone replacement therapy (HRT), a rise in age-related gynecological cancers, higher ovarian cancer cases, prevalence of gynecological diseases, increased healthcare expenditure, and investments in understanding endometriosis mechanisms. Key trends include launching new treatments for oncology and endometriosis, developing menopausal hormone therapies, research investments in gynecology drugs, awareness efforts on contraceptive benefits, product launches for unmet needs, antibody-drug conjugates for ovarian cancers, strategic collaborations for portfolio expansion, and focus on combination therapies to address drug resistance in cancer treatments.

The anticipated increase in the number of women affected by ovarian cancer is expected to drive growth in the global gynecological drugs market. Ovarian cancer, originating in the ovaries as part of the female reproductive system, is effectively managed by gynecological drugs that offer targeted treatment options, improved survival rates, and enhanced quality of life for patients. According to estimates from Globocan, the global incidence of ovarian cancer is projected to reach 434,184 by 2040, thereby fostering the demand for gynecological drugs in the foreseeable future.

Age serves as a significant risk factor for various diseases, including diabetes, obesity, neurodegenerative disorders, and cancer. In particular, disruptions in female reproductive cycles, such as early menarche or late menopause, contribute to hormonal imbalances and increase the risk of cancer in later stages of life. Endometrial and ovarian cancers are prevalent among elderly women and contribute to substantial mortality rates. The incidence of these cancers rises with age, typically peaking around 60 to 70 years. Additionally, cervical cancer is commonly diagnosed around the age of 50, while vaginal and vulvar cancers are typically diagnosed later, around the age of 67. For instance, the American Cancer Society estimates 14,000 new cases of cervical cancer in the United States in 2022. The age-related upswing in gynecological cancers is expected to propel the market in the coming years.

There is a noteworthy trend in the pharmaceutical industry where companies are investing in the development of personalized cancer vaccines, including those for gynecological cancers. Some of these vaccines have progressed to clinical trial phases, demonstrating the industry's commitment to leveraging genetic sequencing and precision medicine for patient-specific drug therapies. Notably, Moderna reported positive results from an ongoing Phase 1 clinical study of its mRNA-4157 personalized cancer vaccine, designed for patients with both resected and unresected solid tumors. The vaccine is currently in Phase 2 clinical trials.

The introduction of gynecological drug treatments by major companies represents a positive trend in the market. Given the competitive landscape and the presence of multiple players, companies are focusing on advanced drug development to introduce new and effective treatments. For example, in September 2021, Myovant Sciences, a UK-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had accepted a supplemental New Drug Application (sNDA) for MYFEMBREE, a drug designed to manage moderate to severe pain associated with endometriosis. The FDA set a target action date of May 6, 2022, for the sNDA under the Prescription Drug User Fee Act (PDUFA).

In March 2022, Carlyle, a U.S.-based private equity firm, and PAI Partners, a France-based private equity firm, reached an agreement to acquire Theramex from CVC Capital Partners for $1.4 billion. This acquisition is intended to expand the investment portfolio of Carlyle and PAI in Theramex, focusing on organic, inorganic, and international growth initiatives. Theramex, a UK-based pharmaceutical company, specializes in women's health products related to fertility, contraception, menopause, and osteoporosis.

Major companies operating in the gynecology drugs market report are Merck & Co. Inc., AbbVie, Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Pfizer Inc., Furukawa Electric, Motherson Sumi, LS Cables & Systems, HUBER+SUHNER., Acome, Yazaki Corporation, Fujikura Ltd., Robert Bosch, HELLA GmbH & Co. KGaA, Coroplast Harness Technology Sp. z oo sp. k, EK Elektrokabel FABRYKA KABLI Karolak i synowie sp. z o.o., Coroflex Poland Sp. z o.o Sp. k., Eltrim Kable Sp. z o. o, Anixter, Allied Wire & Cable Inc., Emcocables, Navcar S.A.S, Wirex Cable SA, Sistemas de Argentina S.A, ARJ Water Technology LLC, Fajr Al Hind LLC, Haji Commercial Co LLC, Bahra Cables, Coficab Group

North America was the largest region in the gynecology drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gynecology drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the gynecology drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The gynecology market consists of sales of belantamab, relugolix, selumitinib, and avapritinib. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gynecology Drugs Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gynecology drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gynecology drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gynecology drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Therapeutics: Hormonal Therapy; Non-Hormonal Therapy
• 2) By Indication: Gynecology Cancers; Menopausal Disorder; Polycystic Ovary Syndrome; Contraception; Other Indications
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: Merck & Co. Inc.; AbbVie; Hoffmann-La Roche Ltd.; GlaxoSmithKline Plc; Pfizer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gynecology Drugs Market Characteristics

3. Gynecology Drugs Market Trends And Strategies

4. Gynecology Drugs Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Gynecology Drugs Market Size and Growth

• 5.1. Global Gynecology Drugs Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Gynecology Drugs Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Gynecology Drugs Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Gynecology Drugs Market Segmentation

• 6.1. Global Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hormonal Therapy
• Non-Hormonal Therapy
• 6.2. Global Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Gynecology Cancers
• Menopausal Disorder
• Polycystic Ovary Syndrome
• Contraception
• Other Indications
• 6.3. Global Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

7. Gynecology Drugs Market Regional And Country Analysis

• 7.1. Global Gynecology Drugs Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Gynecology Drugs Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Gynecology Drugs Market

• 8.1. Asia-Pacific Gynecology Drugs Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Gynecology Drugs Market

• 9.1. China Gynecology Drugs Market Overview
• 9.2. China Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Gynecology Drugs Market

• 10.1. India Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Gynecology Drugs Market

• 11.1. Japan Gynecology Drugs Market Overview
• 11.2. Japan Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Gynecology Drugs Market

• 12.1. Australia Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Gynecology Drugs Market

• 13.1. Indonesia Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Gynecology Drugs Market

• 14.1. South Korea Gynecology Drugs Market Overview
• 14.2. South Korea Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Gynecology Drugs Market

• 15.1. Western Europe Gynecology Drugs Market Overview
• 15.2. Western Europe Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Gynecology Drugs Market

• 16.1. UK Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Gynecology Drugs Market

• 17.1. Germany Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Gynecology Drugs Market

• 18.1. France Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Gynecology Drugs Market

• 19.1. Italy Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Gynecology Drugs Market

• 20.1. Spain Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Gynecology Drugs Market

• 21.1. Eastern Europe Gynecology Drugs Market Overview
• 21.2. Eastern Europe Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Gynecology Drugs Market

• 22.1. Russia Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Gynecology Drugs Market

• 23.1. North America Gynecology Drugs Market Overview
• 23.2. North America Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Gynecology Drugs Market

• 24.1. USA Gynecology Drugs Market Overview
• 24.2. USA Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Gynecology Drugs Market

• 25.1. Canada Gynecology Drugs Market Overview
• 25.2. Canada Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Gynecology Drugs Market

• 26.1. South America Gynecology Drugs Market Overview
• 26.2. South America Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Gynecology Drugs Market

• 27.1. Brazil Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Gynecology Drugs Market

• 28.1. Middle East Gynecology Drugs Market Overview
• 28.2. Middle East Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Gynecology Drugs Market

• 29.1. Africa Gynecology Drugs Market Overview
• 29.2. Africa Gynecology Drugs Market, Segmentation By Therapeutics, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Gynecology Drugs Market, Segmentation By Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Gynecology Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Gynecology Drugs Market Competitive Landscape And Company Profiles

• 30.1. Gynecology Drugs Market Competitive Landscape
• 30.2. Gynecology Drugs Market Company Profiles
  • 30.2.1. Merck & Co. Inc.
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. AbbVie
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Hoffmann-La Roche Ltd.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. GlaxoSmithKline Plc
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Pfizer Inc.
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Gynecology Drugs Market Other Major And Innovative Companies

• 31.1. Furukawa Electric
• 31.2. Motherson Sumi
• 31.3. LS Cables & Systems
• 31.4. HUBER+SUHNER.
• 31.5. Acome
• 31.6. Yazaki Corporation
• 31.7. Fujikura Ltd.
• 31.8. Robert Bosch
• 31.9. HELLA GmbH & Co. KGaA
• 31.10. Coroplast Harness Technology Sp. z oo sp. k
• 31.11. EK Elektrokabel FABRYKA KABLI Karolak i synowie sp. z o.o.
• 31.12. Coroflex Poland Sp. z o.o Sp. k.
• 31.13. Eltrim Kable Sp. z o. o
• 31.14. Anixter
• 31.15. Allied Wire & Cable Inc

32. Global Gynecology Drugs Market Competitive Benchmarking

33. Global Gynecology Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Gynecology Drugs Market

35. Gynecology Drugs Market Future Outlook and Potential Analysis

• 35.1 Gynecology Drugs Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Gynecology Drugs Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Gynecology Drugs Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer